The increase in the number of therapeutic alternatives for both newly diagnosed and
relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario …

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd)
demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with …

Introduction Therapy for patients with multiple myeloma has improved dramatically over the
past decade following the introduction of novel agents and combinations across the disease …

The evolution of cancer treatment has provided increasingly targeted strategies both in the
upfront and relapsed disease settings. Small‐molecule inhibitors and immunotherapy have …

多发性骨髓瘤是一类恶性浆细胞克隆性疾病, 是血液系统中第二大常见恶性肿瘤,
目前仍不能完全治愈. 随着治疗药物的更新换代, 近年来患者用药后的反应率和生存率都有了 …

Background Comparative investigations evaluating the efficacy of pomalidomide‐based
(Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with …

Background To evaluate the efficacy and safety of pomalidomide in combination treatment of
relapsed/refractory multiple myeloma (RRMM). Methods Published clinical trials were …

Introduction: Despite major advances in the therapeutic management of multiple myeloma
(MM), it remains an incurable disease. Several combinations of monoclonal antibodies with …

多发性骨髓瘤(MM) 为浆细胞异常增生的恶性肿瘤, 是发生静脉血栓栓塞症(VTE)
的高风险血液系统肿瘤之一. 凝血纤溶系统紊乱, 炎症因子分泌增多, 血小板过度激活 …

Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and
pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone …